Dispatches from BPI Europe 2016

Roche: Bispecific and complex mAbs driving process development

By Dan Stanton contact

- Last updated on GMT

Roche: Bispecific and complex mAbs driving process development

Related tags: Bispecific antibodies, Monoclonal antibodies

The increasing complexity of biopharmaceuticals is driving process development innovation according to Swiss drug firm Roche.

The methods used to make blockbuster monoclonal antibodies like Herceptin and Avastin are not sufficient to produce next generation biopharmaceuticals according to Wolfgang Kuhne, Roche’s VP of technical development bioprocessing.

He told delegates at the Bioprocess International European Summit in Vienna, Austria that making candidates like ACE910 – a bispecific antibody granted breakthrough designation for haemophilia last September​ – had required a considerable process development effort.

“There are no more classical standard approaches and we have to make a huge effort for our bioprocessing development,”​ he said.

Downstream challenges

The initial stages of making bispecific antibodies are very similar to those used to make ‘simpler’ drugs like Herceptin.

The molecules are produced in bioreactors by cultured Chinese Hamster Ovary (CHO) cells.

The challenge, Kuhne continued, had been the development of purification processes capable of harvesting the innovative molecules.

Established technologies like Protein-A based resins had not proved effective he said, adding that processes like virus removal are also more complex for bispecific antibodies than for mAbs.

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers

Follow us

Products

View more

Webinars